Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ... [Yahoo! Finance]
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: Yahoo! Finance
Oncology Franchise - CINVANTI Net Revenues: $22.6 million for the quarter. Oncology Franchise - CTOL Net Revenues: $2.8 million for the quarter. Product Gross Profit: $23.4 million or 71% for the three months ended September 30, 2024. SG&A Expenses: $23.3 million for the three months ended September 30, 2024. Research and Development Expenses: $4.5 million for the three months ended September 30, 2024. Net Loss: $4.8 million for the three months ended September 30, 2024. Cash and Short Term Investments: $70.9 million as of September 30, 2024. Adjusted EBITDA: Positive $1.4 million operating income after adjustments. Revised Net Revenue Guidance: $140 million to $146 million for the year. Revised Adjusted Operating Expenses Guidance: $101 million to $105 million for the year. Revised Adjusted EBITDA Guidance: Positive $2 million to positive $5 million for the year. Warning! GuruFocus has detected 5 Warning Signs with HRTX. Release Date: November 12, 2024 For
Show less
Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025PR Newswire
- Heron Therapeutics, Inc. (NASDAQ: HRTX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Heron Therapeutics, Inc. (NASDAQ: HRTX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Heron Therapeutics, Inc. (NASDAQ: HRTX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
HRTX
Earnings
- 11/12/24 - In-Line
HRTX
Sec Filings
- 2/4/25 - Form 4/A
- 2/4/25 - Form 4/A
- 2/4/25 - Form 4/A
- HRTX's page on the SEC website